Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ASTRAZENECA - PRODUTOS FARMACÊUTICOS LDA

NIF 502942240
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €7,871,909 81 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €7,871,909 81 contracts
A2 · Late Publication €12,855,230,604 3,423 contracts
Contract published to BASE more than 10 days after the signing date
LOW €12,855,230,604 3,423 contracts
A5 · Threshold Splitting €132,105,465 156 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €132,105,465 156 contracts
A6 · Low Competition €13,406,174 77 contracts
Only one bidder participated in a competitive procedure
MEDIUM €13,406,174 77 contracts
A9 · Price Overrun €128,127 2 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €128,127 2 contracts
A9 · Abnormal Price Reduction €15,665,250,986 1,507 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €15,665,250,986 1,507 contracts
C3 · Missing Mandatory Fields €17,848,995 105 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €17,848,995 105 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

523
€2,438,179,887
175
€541,415,316
263
€535,527,239
540
€523,782,502
84
€523,147,844
133
€506,771,070
76
€505,055,531
39
€497,653,198
77
€494,893,454
180
€474,961,734
67
€464,936,894
56
€457,113,762
231
€416,349,964
36
€411,304,807
37
€402,811,058
68
€399,098,090
172
€369,612,930
73
€354,642,361
139
€342,281,870
32
€326,257,118
Page 1 of 4 · 70 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 2 · 81 contracts

61/8085/2025 - Autorização de Utilização Excecional do Medicamento
PT · 12079133 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€76 2025-12-11
Aquisição de Medicamento Exclusivo ANIFROlumab 150 mg/ml Sol inj Fr 2 ml IV
PT · 11913493 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€6,849 2025-11-04
AQ. URGENTE DIVERSOS MEDICAMENTOS
PT · 11986613 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€78,851 2025-09-02
AQUISIÇÃO URGENTE DIVERSOS MEDICAMENTOS
PT · 11985180 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€78,742 2025-09-02
AQUISIÇÃO URGENTE DE DIVERSOS MEDICAMENTOS
PT · 11943695 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€60,815 2025-08-07
Aquisição Medicamento Tremelimumab 20 mg/ml Sol inj Fr 15 ml IV
PT · 11745598 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€38,000 2025-07-21
1612/2025- Ajuste direto para aquisição de A53311- Acalabrutinib [100 mg; cáp/comp
PT · 12226585 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,387,425 2025-07-17
AQ. URGENTE DIVERSOS MEDICAMENTOS
PT · 11957754 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€20,083 2025-07-15
Aquisição de Medicamentos Exclusivos II
PT · 11576576 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€169,176 2025-07-08
VÁRIOS MEDICAMENTOS
PT · 11525610 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€10,728 2025-05-29
VÁRIOS MEDICAMENTOS
PT · 11447658 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€92,803 2025-05-16
VÁRIOS MEDICAMENTOS
PT · 11316574 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award
€19,154 2025-03-25
VÁRIOS MEDICAMENTOS
PT · 11279412 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€61,032 2025-03-10
Aquisição Tremelimumab (1 x 300 mg / 15 ml)
PT · 11742014 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€20,000 2025-03-07
Ajuste direto para aquisição de A53311- Acalabrutinib [100 mg; cáp/comp]
PT · 11928172 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,260,138 2025-02-25
VÁRIOS MEDICAMENTOS
PT · 11306751 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€43,704 2025-02-24
VÁRIOS MEDICAMENTOS
PT · 11263591 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€76,874 2025-02-19
VÁRIOS MEDIAMENTOS
PT · 11245808 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€17,740 2025-02-07
Aquisição medicamentos anifrolumab inj.conc.perf. 150mg/ml 2ml iv _ tezepelumab caneta 210mg 110mg/ml 1.91ml sc_zirconio 10g; po susp.oral saq; zirconio 5g po susp.oral saq.
PT · 11316240 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€182,732 2025-01-29
VÁRIOS MEDICAMENTOS
PT · 11183425 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€82,797 2025-01-13
VÁRIOS MEDICAMENTOS
PT · 11138788 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields
€53,555 2024-12-17
Ajuste direto para aquisição de A53311- Acalabrutinib [100 mg; cáp/comp] e T1820- Ticagrelor [60 mg; comp]
PT · 11301580 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields +1
€16,971 2024-11-26
Medicamento Tremelimumab 20 mg/ml Sol inj Fr 15 ml IV
PT · 10981724 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€100,000 2024-10-10
Aquisição Medicamento tremelimumab inj. 20mg/mL 15mL
PT · 11004116 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€20,000 2024-10-01
Medicamento Tremelimumab inj. 20mg/mL 15mL
PT · 11003619 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€20,000 2024-09-30
Medicamento Budesonida 160 µg + Formoterol 5 µg + Brometo de glicopirrónio 7.2 µg Susp pressu inal Inal 120 dose(s)
PT · 11004191 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€6,489 2024-09-24
Medicamento Tremelimumab 20 mg/ml Sol inj Fr 15 ml IV
PT · 11003618 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€20,000 2024-09-19
Ciclossilicato de zircónio sódico 5 g Pó susp oral Saq; Ciclossilicato de zircónio sódico 10 g Pó susp oral Saq; e Budesonida160µg+Formoterol 5µg+Brometo de glicopirrónio7.2µg Susp press Inal.
PT · 10929514 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€63,830 2024-09-05
Medicamento tezepelumab caneta 210mg 110mg/ml 1.91ml sc
PT · 10960956 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€6,931 2024-09-04
Acalabrutinib 100 mg Cáps
PT · 11383973 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields
€50,914 2024-08-22
Budesonida + formoterol susp.press.160+4.5 µg/dose 120 doses
PT · 11348512 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields
€6,307 2024-07-26
VÁRIOS MEDICAMENTOS
PT · 10765991 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€9,413 2024-05-29
Medicamento Anifrolumab Inj 150 mg/ml 2 ml
PT · 11360180 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields
€76,522 2024-04-18
AQUISIÇÃO DE BUDESONIDA+FORMOTEROL 160+4,5 MCG/DOSE SUSPENSÃO PRESSURIZADA INALAÇÃO - EMBALAGEM
PT · 9343164 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€29,170 2022-06-28
AQUISIÇÃO DE BENRALIZUMAB 30 MG/ML - CANETA (MEDICAMENTO DO GRUPO 5: APARELHO RESPIRATÓRIO)
PT · 7778705 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€29,390 2021-06-29
AQUISIÇÃO DE BENRALIZUMAB 30 MG/ML - SERINGA
PT · 7778755 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€29,390 2020-11-10
AQUISIÇÃO DE BENRALIZUMAB 30 MG/ML SERINGA - MEDICAMENTO DO GRUPO 5 - APARELHO RESPIRATÓRIO
PT · 6783891 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€51,600 2020-03-10
AQUISIÇÃO DE BENRALIZUMAB 30 MG/ML - SERINGA
PT · 6138123 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€8,600 2019-12-11
AQUISIÇÃO DE MEDICAMENTOS EXCLUSIVOS
PT · 6775454 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€31,738 2019-03-22
157002 - Aquisição de medicamentosCHNM constantes do AQ2014_1 da SPMS Aparelho cardiovascular
PT · 3786480 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,210 2017-01-16
Medicamentos do foro oncológico - com base no CPA 2013/6
PT · 2276080 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2015-10-29
Medicamentos do aparelho cardiovascular - C/ Base no CPA 2014/1
PT · 2290848 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2015-01-29
Medicamentos do foro oncológico - C/ Base no CPA 2014/6
PT · 2293147 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2015-01-22
Aquisição de 60 comprimidos de Propranolol 40mg
PT · 1360370 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,479 2014-08-21
Com Base no CPA 2011_6
PT · 1168051 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2014-04-04
600 comprimidos de Quetiapina 100mg Comp
PT · 907515 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€104 2013-11-13
Aquisição de 60 comprimidos de propranolol 40 mg
PT · 890061 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€2 2013-11-06
Medicamentos de consumo geral e outros
PT · 875664 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€774,226 2013-05-08
MEDICAMENTOS GASERELINA
PT · 811757 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-04-30
MEDICAMENTOS ESOMEPRAZOL
PT · 811840 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-02-01
Next →
Overview
Total Value Won
€15,882,783,063
Contracts Won
4,775
Score 165250 · CRITICAL RISK
NIF
502942240
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • E.J. [P-13b7]
    Gerente
    since 2010-09-23
  • G.N. [P-2825]
    Gerente
    since 2008-06-17
  • J.B. [P-80c4]
    Gerente
    since 2008-06-17
  • M.D. [P-18ef]
    Gerente
    since 2022-08-01
  • M.J. [P-958d]
    Gerente
    since 2020-02-10
  • N.P. [P-b3fe]
    Gerente
    since 2025-07-07
  • A.R. [P-e93b]
    Gerente
    2016-01-04 → 2017-01-31
  • A.L. [P-4505]
    Gerente
    2011-02-09 → 2014-04-02
  • C.S. [P-8924]
    Gerente
    2019-07-01 → 2021-02-01
  • D.R. [P-d3ac]
    Gerente
    2012-03-19 → 2015-05-21
  • E.J. [P-13b7]
    Gerente
    until 2012-03-19
  • G.N. [P-2825]
    Gerente
    until 2011-05-27
  • J.P. [P-7a84]
    Gerente
    2015-05-21 → 2019-07-01
  • J.F. [P-52bd]
    Gerente
    2012-07-24 → 2015-05-21
  • J.B. [P-80c4]
    Gerente
    until 2010-09-23
  • M.D. [P-18ef]
    Gerente
    2017-01-31 → 2020-02-10
  • M.M. [P-af72]
    Gerente
    2020-02-10 → 2022-08-01
  • M.P. [P-6a2e]
    Gerente
    until 2011-02-09
  • M.P. [P-6a2e]
    Gerente
    2011-05-27 → 2012-07-24
  • M.P. [P-6a2e]
    Gerente
    2014-04-02 → 2016-01-04
  • P.M. [P-5912]
    Gerente
    2015-05-21 → 2020-02-10
  • S.P. [P-a960]
    Gerente
    2021-02-01 → 2025-07-07
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned